Raymond James initiated coverage of Evommune (EVMN) with a Strong Buy rating and $40 price target 2026 will be a catalyst-rich year for Evommune, with Phase 2 readouts for EVO756 and Phase 2 data expected for EVO301 in 1H26, the analyst tells investors in a research note. The firm added that, at current levels, it believes Evommune offers a compelling risk-reward with multiple ways to win and the 1H26 EVO756 readout expected to draw the greatest investor attention.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune initiated with a Strong Buy at Raymond James
- Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch
- Evommune participates in a conference call with William Blair
- Evommune initiated with a Buy at H.C. Wainwright
- 3 ‘Strong Buy’ Stocks to Buy Now,12/30/2025, According to Top Analysts